MRNS - Marinus Market Capitalization-to-Revenue Ratio
Marinus Pharmaceuticals attracts scientists with its ethical culture and focus on helping epilepsy patients. After analyzing the price-to-sales ratio dynamics on GURU.Markets, we find that 1.00 expresses the current value of this metric. Orphan drug status grants the company exceptional pricing power, although final revenue depends on insurance fund limits and patent protection.
Metric breakdowns and analytics for Marinus Pharmaceuticals (MRNS)
- price and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Marinus Pharmaceuticals|MRNS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital marinuspharma.com|MRNS - Company Debts|Debt to Book Value Marinus Pharma|MRNS - Company Long-Term Debts|Company Short-Term Debts Marinus Pharmaceuticals|Quick Liquidity Indicator marinuspharma.com
- earnings and valuation multiples indicators:
MRNS - Net Profit|Expected Net Profit Marinus Pharmaceuticals|MRNS - Price to Earnings Ratio|Forward P/E Multiple Marinus Pharmaceuticals|MRNS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Marinus Pharma|MRNS - Operating profit EBITDA|Net earnings per share for the last four quarters Marinus Pharmaceuticals|MRNS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months marinuspharma.com|MRNS - Earnings growth in current year|Earnings growth forecast for next year Marinus Pharmaceuticals
- issuer revenue and sales details:
Fundamental company analysis:MRNS (Marinus Pharmaceuticals, Inc.)
This multiple is calculated as the ratio of market capitalization to total annual revenue, determining the value per unit of revenue within the asset's valuation structure. Amid cost reductions aimed at preserving the pipeline of Marinus Pharmaceuticals (MRNS), the P/S ratio allows for an assessment of whether the business is undervalued or if there is a risk of overpayment against the backdrop of management restructuring following failed clinical trials.
Competing companies
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals, Inc.|Market Cap to Revenue metaviatx.com (MTVA)|P/S Multiple NRXS|HSDT - Price to Sales|Passage Bio, Inc. - Market Cap to Revenue|bionomics.com.au (NEUP) - Price to Sales|Minerva - P/S Multiple|Market Capitalization-to-Revenue Ratio ATHA (Athira Pharma Inc)|ADXN: P/S Multiple|Market Cap to Revenue Ratio ALZN|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|PTIX (Protagenic Therapeutics) - Market Cap to Sales Volume|P/S Multiple KTTA|Price-to-Revenue Coefficient Cortigent|P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Revenue Ratio|Cara Therapeutics Inc. - P/S Multiple|Chromocell Therapeutics (CHRO) - Market Cap to Revenue|ELYM: P/S Multiple|Market Cap to Revenue Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - P/S Multiple|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
